Inhalation Sciences Sweden AB

Inhalation Sciences Sweden AB

ISAB · ST · Healthcare / Medical Devices

0.0516SEK-0.01 (-11.95%)

Price History

Full chart

Market Stats

Previous Close0.0586
Open0.0518
Day Range0.0516 – 0.0566
52-Week Range0.079 – 0.625
Volume180.08K
Market Cap4.15M
P/E (TTM)0.00
Forward P/E107.53
EPS-0.17
Dividend Yield0.00%
Beta-0.25
50-Day Avg0.1438
200-Day Avg0.2526

About

Inhalation Sciences Sweden AB (publ) develops and sells labtech equipment for inhalation research in Sweden. The company offers PreciseInhale, a laboratory system that allows scientists to measure how inhaled particles act in lungs and affect the health; DissolvIt, which enables in vitro simulation of dissolution and absorption of respirable particles in the lung epithelium; XposeALI, a 3D cell exposure module that combines aerosol capability with 3D cell models cultured at an air liquid interface; Nose-only inhalation, a standard method of exposure used in preclinical testing of inhalation drugs, as well as for inhalation toxicity studies in rodents; and intratracheal exposure module, an unique technology delivering aerosol directly to the lungs, bypassing the nose, and to spontaneously breathing rodents. Inhalation Sciences Sweden AB (publ) was incorporated in 2004 and is based in Huddinge, Sweden.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEOMr. Manoush Masarrat
  • Employees5
  • HeadquartersNovum floor 6, Huddinge, Sweden, 141 57, Sweden
  • Websitehttps://www.inhalation.se

Leadership

  • Mr. Manoush MasarratChief Executive Officer · b. 1977
  • Dr. Per GerdeChief Scientific Officer & Director · b. 1953
  • Mr. Ulf WedenbergChief Commercial Officer

Financials

Income Statement

Currency: SEK2022-12-312023-12-312024-12-312025-12-31
Total Revenue12.19M17.50M11.05M3.04M
Growth (%)-+43.55%-36.89%-72.47%
Cost of Revenue2.55M3.54M937.00K456.00K
Gross Profit9.64M13.96M10.11M2.58M
Gross Margin79.08%79.77%91.52%85.00%
Operating Expense21.67M17.72M15.19M12.74M
Operating Income-12.03M-3.76M-5.08M-10.15M
Operating Margin-98.61%-21.46%-45.95%-333.94%
EBITDA-10.84M-2.63M-3.94M-9.69M
EBITDA Margin-88.92%-15.04%-35.70%-318.61%
Net Income-12.13M-4.74M-5.15M-10.16M
Net Income Margin-99.43%-27.10%-46.59%-334.10%
R&D8.84M7.12M6.74M4.15M
R&D as % of Total Revenue72.49%40.65%61.05%136.50%
Interest Expense103.00K995.00K77.00K13.00K
Interest Expense % of Total Revenue0.84%5.68%0.70%0.43%

Balance Sheet

Currency: SEK2022-12-312023-12-312024-12-312025-12-31
Total Assets12.98M18.17M10.53M9.53M
Total Liabilities5.43M5.21M2.72M2.27M
Total Equity7.55M12.95M7.81M7.26M
Cash1.84M7.83M4.45M2.83M

Cash Flow

Currency: SEK2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow---12.01M-3.74M-2.94M-10.79M
Capital Expenditure0040.00K000
Free Cash Flow---12.05M-3.74M-2.94M-10.79M
FCF to OCF--100.33%100.00%100.00%100.00%

Earnings

Report DateSep 30, 2017Dec 31, 2017Mar 31, 2018Jun 30, 2018Sep 30, 2018Dec 31, 2018Mar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate------------------------------------
EPS Actual-0.14-0.22-0.43-0.44-0.41-0.15-0.260.38-0.32-0.260.061.70-0.31-0.44-0.36-0.50-0.35-0.24-0.27-0.32-0.28-0.09-0.18-0.02-0.09-0.06-0.05-0.05-0.06-0.14-0.13-0.11-0.07-0.07-0.03-0.04
Surprise------------------------------------
Timing------------------------------------

Key Statistics & Ratios

Market Cap4.15M
Enterprise Value3.16M
Trailing P/E0.00
Forward P/E107.53
Price / Sales0.50
Price / Book0.77
EPS-0.17
Book Value0.123
Revenue (TTM)8.30M
Gross Profit (TTM)5.33M
EBITDA-8.54M
Profit Margin-103.11%
Operating Margin-64.97%
Return on Equity-90.03%
Return on Assets-47.27%
Shares Outstanding51.20M
Shares Float48.62M
Beta-0.25
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%